Trial Profile
Identification of Plaque Vulnerability Wit PET/MRI: a Feasibility Study of 18F-Flutemetamol in Atherosclerosis
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 14 Jan 2019 Planned End Date changed from 30 Sep 2018 to 31 Dec 2019.
- 14 Jan 2019 Planned primary completion date changed from 30 Sep 2018 to 31 Dec 2019.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.